MedTrace Logo

Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases: Prospective Multicenter Randomized Controlled Trial

NCT05743972 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2023-02-24

No results posted yet for this study

Summary

According to previous studies, contrast-enhanced ultrasound (CEUS) -guided Core Biopsy(GB) could improve the diagnosis of biopsy in liver and other superficial mass compared to conventional US-GB. The purpose of this randomized trial is to estimate whether CEUS-GB achieve excellent diagnostic value to conventional US-GB in percutaneous biopsy for pancreatic diseases.

Conditions

  • Pancreatic Disease

Interventions

DIAGNOSTIC_TEST

Contrast-enhanced ultrasound-guided core biopsy

Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.

DIAGNOSTIC_TEST

Conventional ultrasound-guided core biopsy

Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.

Sponsors & Collaborators

  • xiao-yan xie

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-12-01
Completion
2026-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05743972 on ClinicalTrials.gov